These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3190812)

  • 21. Regulatory aspects of drug dissolution from a European perspective.
    Graffner C
    Eur J Pharm Sci; 2006 Nov; 29(3-4):288-93. PubMed ID: 16950606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioequivalence studies: single vs multiple dose.
    Steinijans VW; Sauter R; Jonkman JH; Schulz HU; Stricker H; Blume H
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S31-6. PubMed ID: 1601529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biopharmaceutical studies of similar theophylline products in the national market].
    Pezoa R; Concha AM; Ramírez M; Alvarez J
    Rev Med Chil; 1997 Mar; 125(3):298-304. PubMed ID: 9460266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Theophylline therapeutic drug monitoring in the case of a new sustained-release pellet formulation for once-daily evening administration.
    Steinijans VW; Trautmann H; Sauter R; Staudinger H
    Arzneimittelforschung; 1988 Aug; 38(8A):1251-3. PubMed ID: 3190814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo-in vitro correlation (IVIVC).
    Hayes S; Dunne A; Smart T; Davis J
    J Pharm Sci; 2004 Mar; 93(3):571-81. PubMed ID: 14762896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative bioavailability and in vitro in vivo correlation of two sustained release brands of theophylline: tablets and pellets.
    Tulain U; Ur-Rahman N
    Pak J Pharm Sci; 2008 Apr; 21(2):131-8. PubMed ID: 18390443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Justification of Drug Product Dissolution Rate and Drug Substance Particle Size Specifications Based on Absorption PBPK Modeling for Lesinurad Immediate Release Tablets.
    Pepin XJ; Flanagan TR; Holt DJ; Eidelman A; Treacy D; Rowlings CE
    Mol Pharm; 2016 Sep; 13(9):3256-69. PubMed ID: 27438964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substitution of theophylline slow-release formulations according to the rebate contracts in the German statutory health insurance.
    Weissenfeld J; Lüngen M; Stock S; Drabik A; Gerber A
    Arzneimittelforschung; 2009; 59(9):476-81. PubMed ID: 19856796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Role of food interaction pharmacokinetic studies in drug development. Food interaction studies of theophylline and nifedipine retard and buspirone tablets].
    Drabant S; Klebovich I; Gachályi B; Renczes G; Farsang C
    Acta Pharm Hung; 1998 Sep; 68(5):294-306. PubMed ID: 9805816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioequivalence of two brands of sustained release theophylline brands.
    Bhandari P
    J Assoc Physicians India; 1999 Apr; 47(4):461. PubMed ID: 10778546
    [No Abstract]   [Full Text] [Related]  

  • 34. [Release, absorption and elimination of theophylline from fast and slowly released oral formulations].
    Frömming KH; Schwabe L; Staib AH; Rietbrock N; Lassmann A; Molz KH; Schuppan D; Siebert-Weigel M; Voegele D
    Arzneimittelforschung; 1983; 33(3):446-52. PubMed ID: 6683521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo-in vitro correlations with sustained-release theophylline preparations.
    Ritschel WA; Koch HP; Alcorn GJ
    Methods Find Exp Clin Pharmacol; 1984 Oct; 6(10):609-18. PubMed ID: 6513678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacokinetics of a theophylline sustained-release formulation after single and twice daily dosage].
    Fuchs WS; von Nieciecki A; Pabst G; Müller M; Dilger C; Gay S; Laicher A; Stanislaus F
    Arzneimittelforschung; 1998 May; 48(5A):589-92. PubMed ID: 9676350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses.
    Tröger U; Martens J; Meyer FP; Hoffmann A; Terhaag B
    Arzneimittelforschung; 1995 Dec; 45(12):1266-70. PubMed ID: 8595082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Theophylline controlled-release formulations: in vivo-in vitro correlations.
    Yu Z; Schwartz JB; Sugita ET
    Biopharm Drug Dispos; 1996 Apr; 17(3):259-72. PubMed ID: 8983400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system.
    Möller H; Wirbitzki E
    Boll Chim Farm; 1993 Apr; 132(4):105-15. PubMed ID: 8333916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Setting dissolution specifications for modified-release dosage forms.
    Piscitelli DA; Young D
    Adv Exp Med Biol; 1997; 423():159-66. PubMed ID: 9269491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.